Intermountain Health, the largest nonprofit healthcare provider in the Intermountain West region, struck a multi-year collaboration with a young generative AI startup this month. The health system is ...

As previously reported, the single agent dose escalation of BI-1910 in the Phase 1 study was completed without any notable adverse eventsUpdated clinical data will be presented at the Society for ...

TNG260 is a first-in-class, highly selective CoREST complex inhibitor currently being evaluated with pembrolizumab in the dose expansion phase of the TNG260 Phase 1/2 trial. The trial is currently ...

The positive preliminary SENTI-202 clinical data was presented on April 27 in a Clinical Trials Oral Minisymposium at the American Association for Cancer Research (AACR) Annual Meeting 2025 in an ...

Nonclinicians were trained to abstract the diagnosis of GBM from EHRs, and their accuracy was compared with abstraction performed by clinicians. The resulting data were used to build a cohort of ...